(Rac)-Modipafant|122956-68-7|(UK-74505)-陌孚医药/Medlife

您当前的位置：

(Rac)-Modipafant (Synonyms: UK-74505)

目录号: PL12087 纯度: ≥98%

CAS No. :122956-68-7

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	(Rac)-Modipafant
中文别名	外消旋-莫地帕泛
英文名称	(Rac)-Modipafant
英文别名	3-Pyridinecarboxylicacid,4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-[4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]-5-[(2-pyridinylamino)carbonyl]-,ethyl ester;modipafant;rac-Modipafant;3-Pyridinecarboxylicacid,4-(2-chlorophenyl)-1,4-dihydro-6-methyl-2-[4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]-5-[(2-p;ethyl 4-(2-chlorophenyl)-6-methyl-2-[4-(2-methylimidazo[4,5-c]pyridin-1-yl)phenyl]-5-(pyridin-2-ylcarbamoyl)-1,4-dihydropyridine-3-carboxylate;UK-74505;Modipefant;ethyl 4-(2-chlorophenyl)-6-methyl-2-(4-(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl)-5-(pyridin-2-ylcarbamoyl)-1,4-dihydropyridine-3-carboxylate(WXG02205);4-(2-Chlorophenyl)-1,4-dihydro-6-Methyl-2-[4-(2-Methyl-1H-iMidazo[4,5-c]pyridin-1-yl)phenyl]-5-[(2-pyridinylaMino)carbonyl]-3-pyridinecarboxylic Acid Ethyl Ester;2-[4-(2-Methyl-1H-imidazo[4,5-c]pyridin-1-yl)phenyl]-4-(2-chlorophenyl)-5-[(2-pyridinylamino)carbonyl]-6-methyl-1,4-dihydropyridine-3-carboxylic acid ethyl ester;(Rac)-Modipafant
Cas No.	122956-68-7
分子式	C₃₄H₂₉N₆O₃Cl
分子量	605.09
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情	(Rac)-Modipafant (UK-74505) 是一种口服的、选择性的、长效的不可逆血小板活化因子受体 (PAFR) 受体拮抗剂。(Rac)-Modipafant 预防严重登革热感染。
生物活性	(Rac)-Modipafant (UK-74505) is an orally active, selective, long-acting irreversible platelet activating factor receptor (PAFR) antagonist. (Rac)-Modipafant prevents dengue infection.
性状	Solid
体内研究(In Vivo)	(Rac)-Modipafant (UK-74505) (10 mg/kg; p.o.; twice a day until day 10) prevents Severe Dengue Infection. (Rac)-Modipafant exhibits highly selective, time-dependent inhibition of PAF-induced aggregation of rabbit washed platelets (IC 50 =26.3 and 1.12 nM after 0.25 and 60 min preincubation, respectively). (Rac)-Modipafant (5-20 mg/kg; p.o.) dose-dependently inhibits the Zymosan -induced articular hyperalgesia. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. OConnor BJ, et al. Inhibitory effect of UK,74505, a potent and specific oral platelet activating factor (PAF) receptor antagonist, on airway and systemic responses to inhaled PAF in humans. Am J Respir Crit Care Med. 1994;150(1):35-40. [2]. Alabaster VA, et al. UK-74,505, a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo. Agents Actions Suppl. 1991;34:221-227.

溶解度数据	In Vitro: DMSO : 50 mg/mL (82.63 mM; Need ultrasonic)配制储备液

搜索质检报告(COA)

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品